ADEA vs DBD
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ADEA · Adeia$15.50 ▲ 4.59%
DBD · Diebold Nixdorf$58.27 ▼ 0.10%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ADEA +10.3%
- DBD -10.4%
Head to head
| Metric | ADEA | DBD |
|---|---|---|
| Price | $15.50 | $58.27 |
| Change today | ▲ 4.59% | ▼ 0.10% |
| Market cap | $1.71B | $1.96B |
| Return, 3 months | -44.3% | -18.7% |
| Return, year to date | -9.6% | -14.2% |
| Return, 1 year | +12.7% | -9.7% |
| P/E (TTM) | 15.0 | 27.6 |
| P/B | 3.5 | 2.1 |
| P/E percentile vs own 5y | 43rd | 86th |
| Dividend yield | 1.29% | – |
| Revenue growth (YoY, latest qtr) | +12.1% | +5.2% |
| Net profit growth (YoY) | +3.9% | -83.0% |
| Gross margin | – | 25.0% |
| Operating margin | 46.5% | 6.2% |
| Net margin | 26.1% | 2.0% |
| Return on equity | 27.9% | 7.5% |
| Analyst target vs. price | +177.4% | +45.9% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 25 | 38 |
| 30-day volatility | 75.7% | 54.6% |
| Max drawdown, 1 year | -55.8% | -39.3% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- DBD is the largest of the group by market value.
- ADEA has returned the most over the past year.
- ADEA carries the lowest trailing P/E.
- ADEA is growing revenue fastest.
- ADEA keeps the most profit per dollar of sales.
- DBD has been the calmest stock over the last 30 days.